You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Citation Tools

Article menu
Cardiovascular and metabolic risk
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dagogo-Jack S, Pratley RE, Cherney DZI, et al
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
BMJ Open Diabetes Research and Care 2021;9:e002484. doi: 10.1136/bmjdrc-2021-002484